May 14, 2021 / 12:30PM GMT
Louise Barrett - Iterum Therapeutics plc - SVP of Legal Affairs & Secretary
Good morning, and welcome to Iterum Therapeutics' First Quarter 2021 Financial Results Conference Call. A press release with the company's first quarter results was issued earlier this morning and can be found on our website. We are joined this morning by Corey Fishman, CEO; and Judy Matthews, CFO. Corey will provide some opening remarks. Judy will provide details on our financial results, and then we'll open the lines for Q&A.
Before we begin, I would just like to remind you that this call will contain forward-looking statements concerning our plans, strategies and prospects for our business, including with respect to the timing of review for the FDA of our NDA for oral sulopenem and related PDUFA date; the holding of an FDA Advisory Committee meeting to discuss the NDA; our expectations for potential approval on the PDUFA date; the market potential for sulopenem; commercialization activities, including the ability to enter into a definitive agreement with respect to commercialization services and to successfully
Q1 2021 Iterum Therapeutics PLC Earnings Call Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers